Below are our currently enrolling studies for patients with different forms of lupus.
Sponsor: UCB Biopharma SRL
Protocol Number: SL0044
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Detailed Information:
To learn more or see if you qualify: Click Here
